NetworkNewsBreaks – Zenosense, Inc.’s (ZENO) M
Post# of 53
Zenosense (OTC: ZENO) recently reported the successful completion of a second round of testing for its MIDS Cardiac™ device, a patented handheld point-of-care (“POC”) technology for the detection of heart attack. An article discussing the device reads: “According to the World Health Organization, early detection is one of the most important prerequisites for the successful management of cardiovascular problems. … With detection equal or superior to state of the art laboratory analyzers and advanced portability allowing it to be used at point of care, including in an emergency setting, MIDS Cardiac™ would be an absolute game changer which could help save lives and money by enabling a swift diagnosis with previously unheard of accuracy at the point of care (http://nnw.fm/8ZAlr).”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer